Bullfrog AI Holdings, Inc. (BFRG) is a Gaithersburg, Maryland-based digital biopharmaceutical company that sells an artificial intelligence and machine learning analytics platform, bfLEAP, to drug developers, and also advances its own early-stage candidates in glioblastoma and metabolic disease. Shares were quoted at $0.49 on Monday morning, down 7.55% from the prior close of $0.53, putting the micro-cap on track for its second straight down session. The move lower follows Friday's third-quarter release and a post-earnings conference call held after that day's closing bell, which left Monday as the first full session in which investors could react to management's commentary alongside the 10-Q.
The revenue line is the crux of the selling. Bullfrog AI booked $63,578 of collaboration revenue in the quarter ended September 30, against $83,413 a year earlier and a consensus estimate near $215,000 — a shortfall of roughly 70%. That follows a much stronger second quarter, when the company recognized $215,385 after completing the first deliverable under its agreement with a top-five global pharmaceutical partner covering major depressive disorder.
The swing highlights the lumpiness of a milestone-based model with a single anchor client. Operating expenses rose to $2.06 million from $1.66 million, producing an operating loss of $2.05 million versus $1.57 million. The reported per-share loss of $0.11 also came in wider than the $0.09 consensus, though it improved from $0.15 a year earlier. For a company with a market value near $9 million, a quarterly revenue figure in the tens of thousands is a material signal about how slowly commercialization is scaling.
The 10-Q added a second layer of pressure. Common shares outstanding stood at 18.69 million as of November 12, up from 11.42 million at December 31, 2025 — growth of roughly 64% in under a year, driven by equity raises used to fund operations and satisfy listing requirements. Cash and equivalents rose to $4.99 million from $2.18 million over the same period, so the balance sheet is stronger, but each dollar of that improvement came at the cost of a larger share count. With first-half losses running near $3 million and additional equity capacity in place, investors are weighing the runway against further issuance risk.
Bullfrog AI did not fall in a vacuum. Monday's session was broadly risk-off, with the Nasdaq-100 proxy QQQ down 1.96%, the S&P 500 proxy SPY off 1.14%, small caps as measured by IWM down 0.94% and the biotech benchmark XBI lower by 1.35%. Pre-revenue and early-revenue names with high beta typically underperform on days like this, and the company-specific disappointment compounded the drag. The decline is therefore best read as company news plus macro beta rather than a sector-specific event.
Turnover has picked up meaningfully. More than 50,000 shares traded in the first hour of Monday's session, against an average of roughly 115,000 a day over the prior nine sessions — a pace consistent with a full day above recent norms. The stock gapped lower at the open near $0.50 and has traded in a $0.48 to $0.52 band, briefly printing a $0.48 low. That puts shares beneath both the 50-day moving average around $0.55 and the 200-day average near $0.64, and roughly 13% above the 52-week low of $0.425. Momentum has faded since the September spike that briefly carried the stock above $1.00 on insider buying and the depression-target data.
The score runs from 0 — no meaningful news and a move typical for the stock — to 100, meaning transformative news plus an extreme, rare price move. Bullfrog AI lands at 28 out of 100.
The verified news is genuine but small in absolute terms: a quarterly revenue line that missed by roughly 70%, a wider operating loss, and a share count up 64% year to date. The price move, however, is only about 1.4 times the stock's average absolute daily change of roughly 5.5% over the past 60 sessions, and moves of this size or larger occurred eight times in that window. Weak-to-moderate news combined with an unremarkable move for this name produces a low-to-mid score.
Attention now shifts to the fourth quarter, where the single analyst covering the name looks for a loss of about $0.10 a share on roughly $350,000 of revenue. The central question is whether the top-five pharmaceutical partner converts the completed depression-target work into a second paid program, and whether any new clients sign. Investors will also track cash consumption against the $4.99 million balance, any use of the remaining equity line, and the stock's distance from the $1 minimum bid threshold that triggered a Nasdaq notice earlier this year. Sector sentiment toward small-cap AI drug-discovery names remains a swing factor, and the shares carry elevated risk given thin liquidity, a concentrated client base and continued funding needs.
Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are surfaced in its curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the lineup rotates as market conditions shift. For traders looking to pair discretionary ideas with systematic execution, reviewing the current leaders is a practical next step.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Stochastic Oscillator for BFRG moved out of overbought territory on November 13, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 26 similar instances where the indicator exited the overbought zone. In 25 of the 26 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BFRG as a result. In 76 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
BFRG moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BFRG crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BFRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
BFRG broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BFRG entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Moving Average Convergence Divergence (MACD) for BFRG just turned positive on November 04, 2026. Looking at past instances where BFRG's MACD turned positive, the stock continued to rise in 31 of 33 cases over the following month. The odds of a continued upward trend are 90%.
Following a +15.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BFRG advanced for three days, in 118 of 148 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.375) is normal, around the industry mean (4.523). P/E Ratio (-1.126) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. BFRG's P/S Ratio (19.268) is slightly higher than the industry average of (6.105).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. BFRG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BFRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ServicestotheHealthIndustry